MMY1001 subgroup: daratumumab-Kd in lenalidomide refractory MM

While there are many clinical trials exploring the effect of various novel agents in combination with lenalidomide-dexamethasone therapy in multiple myeloma (MM), patients who are lenalidomide refract... Author: VJHemOnc Added: 07/27/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts